Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.lfs.2020.118054 http://scihub22266oqcxt.onion/10.1016/j.lfs.2020.118054 32663575!7832727!32663575     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Life+Sci 2020 ; 257 (ä): 118054 Nephropedia Template TP {{tp|p=32663575|t=2020. Tackling the cytokine storm in COVID-19, challenges and hopes |pdf=|usr=}}{{32663575}} gab.com Text Tackling the cytokine storm in COVID-19, challenges and hopes JO: Life Sci http://www.kidney.de/pget.php?&tw=1&pmid=32663575 #FOAvip The outbreak of Coronavirus disease 2019 (COVID-19) is the current world health concern, presenting a public health dilemma with ascending morbidity and mortality rates exceeding any previous viral spread, without a standard effective treatment yet. SARS-CoV-2 infection is distinguished with multiple epidemiological and pathological features, one of them being the elevated levels of cytokine release, which in turn trigger an aberrant uncontrolled response known as "cytokine storm". This phenomenon contributes to severe acute respiratory distress syndrome (ARDS), leading to pneumonia and respiratory failure, which is considered a major contributor to COVID-19-associated fatality rates. Taking into account that the vast majority of the COVID-19 cases are aggravated by the respiratory and multiorgan failure triggered by the sustained release of cytokines, implementing therapeutics that alleviate or diminish the upregulated inflammatory response would provide a therapeutic advantage to COVID-19 patients. Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients. In this review, we have critically compared the clinical impact of several potential therapeutic agents that could block or interfere with the cytokine storm, such as IL-1 inhibitors, IL-6 inhibitors, mast cell targeting agents, and corticosteroids. This work focused on highlighting and contrasting the current success and limitations towards the involvement of these agents in future treatment protocols. Twit Text FOAVip Tackling the cytokine storm in COVID-19, challenges and hopes ????Life Sci http://www.kidney.de/pget.php?&tw=1&pmid=32663575 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32663575 #FOAvip English Wikipedia <ref>{{Cite pmid|32663575}}</ref> Tackling the cytokine storm in COVID-19, challenges and hopes #MMPMID32663575 Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA Life Sci 2020[Sep]; 257 (ä): 118054 PMID32663575show ga The outbreak of Coronavirus disease 2019 (COVID-19) is the current world health concern, presenting a public health dilemma with ascending morbidity and mortality rates exceeding any previous viral spread, without a standard effective treatment yet. SARS-CoV-2 infection is distinguished with multiple epidemiological and pathological features, one of them being the elevated levels of cytokine release, which in turn trigger an aberrant uncontrolled response known as "cytokine storm". This phenomenon contributes to severe acute respiratory distress syndrome (ARDS), leading to pneumonia and respiratory failure, which is considered a major contributor to COVID-19-associated fatality rates. Taking into account that the vast majority of the COVID-19 cases are aggravated by the respiratory and multiorgan failure triggered by the sustained release of cytokines, implementing therapeutics that alleviate or diminish the upregulated inflammatory response would provide a therapeutic advantage to COVID-19 patients. Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients. In this review, we have critically compared the clinical impact of several potential therapeutic agents that could block or interfere with the cytokine storm, such as IL-1 inhibitors, IL-6 inhibitors, mast cell targeting agents, and corticosteroids. This work focused on highlighting and contrasting the current success and limitations towards the involvement of these agents in future treatment protocols. |Adrenal Cortex Hormones/pharmacology[MESH] |Anti-Inflammatory Agents/pharmacology[MESH] |Betacoronavirus/immunology/pathogenicity[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/*immunology/pathology/virology[MESH] |Coronavirus/immunology/pathogenicity[MESH] |Cytokines/immunology[MESH] |Dexamethasone/*pharmacology[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/*immunology/pathology/virology[MESH] |Respiratory Distress Syndrome/drug therapy[MESH]Tackling the cytokine storm in COVID-19, challenges and hopes (epmc).pdf DeepDyve Pubget Overpricing